Individualized, discrete event, simulations provide insight into inter- and intra-subject variability of extended-release, drug products

Objective Develop and validate particular, concrete, and abstract yet plausible in silico mechanistic explanations for large intra- and interindividual variability observed for eleven bioequivalence study participants. Do so in the face of considerable uncertainty about mechanisms.